Hubbry Logo
Bloodless surgeryBloodless surgeryMain
Open search
Bloodless surgery
Community hub
Bloodless surgery
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Bloodless surgery
Bloodless surgery
Bloodless surgery
View on Wikipedia
from Wikipedia

Bloodless surgery is a non-invasive surgical method developed by orthopedic surgeon Adolf Lorenz, who was known as "the bloodless surgeon of Vienna".[1][2][3][4] His medical practice was a consequence of his severe allergy to carbolic acid routinely used in operating rooms of the era. His condition forced him to become a "dry surgeon".[5] Contemporary usage of the term refers to both invasive and noninvasive medical techniques and protocols.[6] The expression does not mean surgery that makes no use of blood or blood transfusion. Rather, it refers to surgery performed without transfusion of allogeneic blood.[7][8] Champions of bloodless surgery do, however, transfuse products made from allogeneic blood (blood from other people) and they also make use of pre-donated blood for autologous transfusion (blood pre-donated by the patient).[9] Interest in bloodless surgery has arisen for several reasons. Jehovah's Witnesses reject blood transfusions on religious grounds; others may be concerned about bloodborne diseases, such as hepatitis and AIDS.

History

[edit]

During the early 1960s, American heart surgeon Denton Cooley successfully performed numerous bloodless open-heart surgeries on Jehovah's Witness patients. Fifteen years later, he and his associate published a report of more than 500 cardiac surgeries in this population, documenting that cardiac surgery could be safely performed without blood transfusion.[10]

Ron Lapin (1941–1995) was an American surgeon, who became interested in bloodless surgery in the mid-1970s. He was known as a "bloodless surgeon" due to his willingness to perform surgeries on severely anemic Jehovah's Witness patients without the use of blood transfusions.

Patricia A. Ford (born 1955) was the first surgeon to perform a bloodless bone marrow transplant.[11]

In 1988, Professor James Isbister, a haematologist from Australia, first proposed a paradigm shift back to a patient focus. In 2005, he penned an article in the journal, 'Updates in Blood Conservation and Transfusion alternatives'. In this article Prof. Isbister coined the term 'patient blood management', noting that the focus should be changed from the product to the patient.

Principles

[edit]

Several principles of bloodless surgery have been published.[12]

Preoperative techniques such as erythropoietin (EPO) or iron administration are designed to stimulate the patient's own erythropoiesis.

In surgery, control of bleeding is achieved with the use of laser or sonic scalpels, minimally invasive surgical techniques, electrosurgery and electrocautery, low central venous pressure anesthesia (for select cases), or suture ligation of vessels.[13] Other methods include the use of blood substitutes, which at present do not carry oxygen but expand the volume of the blood to prevent shock. Many doctors view acute normovolemic hemodilution, a form of storage of a patient's own blood, as a pillar of "bloodless surgery" but the technique is not an option for patients who refuse autologous blood transfusions.

Intraoperative blood salvage is a technique which recycles and cleans blood from a patient during an operation and redirects it into the patient's body.

Postoperatively, surgeons seek to minimize further blood loss by continuing administration of medications to augment blood cell mass and minimizing the number of blood draws and the quantity of blood drawn for testing, for example, by using pediatric blood tubes for adult patients.[13] Hemoglobin-Based Oxygen Carriers such as Polyheme and Hemepure have been discontinued due to severe adverse reactions including death. South Africa was the only country where they were legally authorized as standard treatment but they are no longer available.

Benefits

[edit]

Bloodless medicine appeals to many doctors because it carries low risk of post-operative infection when compared with procedures requiring blood transfusion. Additionally, it may be economically beneficial in some countries. For example, the cost of blood in the US hovers around $500 a unit, including testing.[14] These costs are further increased as, according to Jan Hoffman (an administrator for the blood conservation program at Geisinger Medical Center in Danville, Pennsylvania), hospitals must cover the cost of the first three units of blood infused per patient per calendar year.[citation needed] By contrast, hospitals may be reimbursed for drugs that boost a patient's red blood cell count, a treatment approach often used before and after surgery to reduce the need for a blood transfusion.[citation needed] However, such payments are highly contingent upon negotiations with insurance companies. Geisinger Medical Center began a blood conservation program in 2005 and reported a recorded savings of $273,000 in its first six months of operation.[15] The Cleveland Clinic lowered their direct costs from US$35.5 million in 2009 to $26.4 million in 2012—a savings of nearly $10 million over 3 years.[16]

Health risks appear to be another contributing factor in their appeal, especially in light of recent studies that suggest that blood transfusions can increase the risk of complications and reduce survival rates.[17][18] Thus, patients who do not receive blood products during hospitalization often recover more quickly, experience fewer complications, and are able to be discharged home more quickly.

See also

[edit]
  • Knocking, a documentary on Jehovah's Witnesses that features a bloodless liver transplant

References

[edit]

Sources

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Bloodless surgery

View on Grokipedia
from Grokipedia
Bloodless surgery encompasses surgical procedures conducted without the administration of allogeneic blood transfusions or stored blood products, emphasizing strategies to preserve and optimize the patient's endogenous blood resources through multidisciplinary perioperative management. This approach integrates preoperative correction via iron supplementation and erythropoiesis-stimulating agents, intraoperative blood conservation techniques such as cell salvage and hemostatic agents like , and postoperative measures to tolerate lower thresholds while minimizing diagnostic blood draws. Originating from necessities posed by patients refusing transfusions on religious grounds, such as , it has evolved into a systematic framework known as patient blood management, applicable across elective and emergent surgeries including cardiac, orthopedic, and oncologic interventions. Empirical evidence from risk-adjusted studies indicates that bloodless surgery yields clinical outcomes comparable to or better than transfusion-inclusive practices, with reduced in-hospital mortality (0.7% versus 2.7% in controls), similar rates of composite morbid events after propensity matching, and discharge levels of approximately 10.8 g/dL. Benefits include lower transfusion-related risks such as infections and immunomodulatory effects, decreased overall healthcare costs (up to 18% reduction in direct costs), and shorter hospital stays, as supported by meta-analyses in high-blood-loss procedures. Systematic reviews of cardiac surgeries in transfusion-refusing cohorts confirm early postoperative safety, with no increased adverse events when optimal blood management protocols are followed. While effective in most cases, bloodless surgery demands rigorous preoperative planning to mitigate risks in profound ( below 5 g/dL in 4.4% of patients versus 0.4% in controls), though such extremes do not correlate with elevated mortality in large cohorts. Its adoption challenges conventional reliance on transfusions, promoting evidence-based thresholds that harness physiological tolerance to , thereby advancing causal understanding of blood loss impacts on outcomes.

Historical Development

Early Origins

Prior to the development of reliable techniques in the early , surgical procedures were constrained by the inability to replace lost effectively, compelling surgeons to prioritize hemorrhage control to avert . Common methods included compressing major vessels prior to incision, employing tourniquets for limb procedures, and swiftly ligating bleeders during operations, which limited interventions to swift, localized interventions rather than extensive resections. A pivotal innovation in intentional bloodless surgery arose in orthopedics with Adolf Lorenz (1854–1946), an Austrian surgeon based in , who systematized non-incisional manipulations around 1900 to address congenital deformities and fractures. Lorenz's approach for congenital entailed gradual traction, manual repositioning under minimal , and fixation via successive plaster spica casts in abduction and external , enabling reduction without opening the or incurring significant blood loss. Similar closed techniques applied to involved serial casting after tendon stretching, while corrections utilized pulley systems and body casts, transforming manipulation from ad hoc practice into a precise, reproducible method. By 1900, Lorenz had treated over 1,000 cases of with these bloodless reductions, as detailed in his publication On the Healing of Congenital Hip Dislocation. These empirical techniques yielded observable advantages in the pre-antibiotic era, including markedly lower postoperative rates compared to open surgeries, as avoiding incisions precluded and —a prevalent cause of operative mortality despite emerging antisepsis protocols. Lorenz's methods underscored the feasibility of achieving structural corrections through mechanical means alone, driven by the era's transfusion limitations rather than elective avoidance.

Mid-20th Century Advancements

In the post-World War II era, the expansion of national blood collection programs, such as the U.S. government's 1940 initiative scaled up in the with plastic bags for safer storage, increased transfusion availability but highlighted safety risks including posttransfusion (PTH), with incidence rates exceeding 10% in some studies of surgical patients. These outbreaks, linked primarily to non-A, non-B from unscreened donor blood—particularly from paid donors showing up to fourfold higher risk—drove early incentives for blood conservation to limit exposure, as evidenced by prospective studies quantifying PTH morbidity and prompting protocols to tolerate lower thresholds during surgery. Surgical advancements from the through the emphasized precision to minimize intraoperative blood loss independently of transfusions, including refined hemostatic techniques like ligature improvements and early electrocautery adoption for vessel , which reduced hemorrhage in procedures such as vascular repairs. Concurrently, evolved with more accurate delivery systems, including ether-oxygen vaporizers and closed-circuit machines developed during wartime and refined postwar, enabling stable and controlled to curtail without relying on volume replacement via transfusion. Autologous blood reinfusion techniques emerged as a key conservation method in the , with intraoperative cell salvage gaining traction through centrifugal separation of cells from shed , first documented in human applications like (TURP) by Wilson and Taswell in , who introduced washing to remove contaminants. This built on prior filtration attempts but marked a shift to viable reinfusion, with devices like Klebanoff's 1968 autotransfusion system enabling processing of up to several units per procedure, directly addressing transfusion risks amid concerns. These innovations laid groundwork for broader acceptance, correlating with observed declines in PTH as surgeons prioritized minimal viable use.

Contemporary Expansion

The surge in bloodless surgery protocols from the 1970s onward was primarily catalyzed by demands from Jehovah's Witnesses, whose religious prohibition against blood transfusions necessitated hospital adaptations amid rising evidence of transfusion-associated risks, including hepatitis outbreaks in the 1970s.31069-3/fulltext) This advocacy prompted early experimental approaches to minimize blood loss, evolving into structured programs as awareness of infectious complications grew. By the 1980s, dedicated bloodless centers emerged, with institutions like Englewood Hospital and Medical Center developing comprehensive protocols that served as models for patient blood management, initially tailored for high-risk procedures. These efforts expanded rapidly; by 1990, only a handful of U.S. hospitals offered such programs, but the number reached 76 by 1998, reflecting formalized integration into surgical practice. The 1990s marked a pivotal advancement with the incorporation of recombinant human (EPO), approved by the U.S. on June 1, 1989, for treating in chronic renal failure patients. This synthetic hormone stimulated endogenous production, enabling preoperative optimization to thresholds compatible with transfusion avoidance, thus broadening applicability to elective surgeries. Hospitals increasingly adopted multidisciplinary teams for bloodless care, coordinating with surgical techniques to accommodate not only religious patients but also those concerned about donor blood scarcity or immunomodulatory effects. Post-2000, peer-reviewed studies reinforced the efficacy of bloodless strategies, particularly highlighting lower postoperative rates in non-transfused cohorts compared to transfused ones. For instance, a 2009 analysis of over 31,000 patients found that reducing transfusion rates correlated with decreased in-hospital infections, projecting a drop from observed levels to 11.8% at lower transfusion thresholds. Additional research confirmed that even 1-2 units of allogeneic blood increased morbidity risks, including infections, prompting global dissemination of protocols beyond specialized centers to mainstream institutions. This evidence, coupled with cost savings from shorter stays and fewer complications, drove adoption in diverse settings, with programs now operational in major health systems worldwide.

Core Principles and Techniques

Preoperative Patient Optimization

Preoperative optimization in bloodless surgery emphasizes the systematic detection and correction of to elevate levels and enhance oxygen-carrying capacity, thereby minimizing reliance on allogeneic blood products. , defined as below 13 g/dL in men and 12 g/dL in non-pregnant women, is prevalent in 30-50% of patients scheduled for elective major surgery and independently predicts adverse outcomes including prolonged hospital stays and increased mortality. Initial evaluation involves comprehensive laboratory testing, including , count, iron studies (serum ferritin, ), , , and levels, to identify underlying etiologies such as , nutritional deficits, or chronic disease. Targeted interventions prioritize intravenous iron for , which corrects deficits more rapidly than oral routes by bypassing gastrointestinal absorption limitations and achieving increases of 1-2 g/dL within 2-4 weeks in preoperative settings. -stimulating agents like recombinant human (EPO), administered at doses of 300-600 IU/kg weekly, stimulate red cell production and yield similar gains of 1-2 g/dL when combined with iron, particularly in patients with endogenous EPO deficiency such as those with . and supplementation address megaloblastic anemias, with intramuscular B12 (1 mg weekly) or oral folate (1-5 mg daily) restoring normal in deficient states, though these are less common in surgical cohorts without prior or dietary issues. Patient selection for bloodless protocols relies on validated risk stratification tools, including the for cardiovascular events or procedure-specific transfusion probability scores, to gauge baseline physiological reserve and expected blood loss. Suitable candidates exhibit stable comorbidities, hemoglobin thresholds above 10 g/dL post-optimization, and low-to-moderate surgical invasiveness; extreme cases—such as acute hemodynamic instability, uncorrectable coagulopathies, or high-bleed procedures in frail elderly patients—are deemed unsuitable to avoid prohibitive morbidity. Empirical data from randomized trials and meta-analyses indicate that such optimization reduces perioperative transfusion requirements by 40-50%, exemplified by a risk ratio of 0.55 for transfusions with EPO plus iron versus , thereby decreasing intraoperative triggers for pharmacologic or cell salvage. This approach enhances tissue perfusion resilience, with cohort studies reporting 20-30% fewer escalations to acute interventions in optimized versus non-optimized groups.

Intraoperative Blood Conservation Methods

Intraoperative blood conservation encompasses techniques applied during to limit hemorrhage, autologous blood, and maintain hemodynamic stability without allogeneic transfusion. These methods leverage hemostatic physiology, including enhancement and volume preservation, to counteract surgical trauma-induced . Key approaches include mechanical salvage systems, dilution strategies, controlled , antifibrinolytic agents, and specialized surgical instruments that promote precise tissue dissection and . Cell salvage, or intraoperative , involves aspiration of shed blood from the surgical field, followed by , , and washing to remove debris, plasma, and activated clotting factors before reinfusion. This recovers approximately 60% to 80% of lost red blood cells, significantly reducing the need for allogeneic units, as demonstrated in meta-analyses of spine surgeries where it lowered transfusion rates without increasing complications. Safety is established in elective procedures, with rates below 1% in large reviews, though contraindications include risks in bacterially infected fields or due to potential tumor cell recirculation. Acute normovolemic hemodilution entails withdrawing 1 to 2 units of at incision, replacing it with crystalloids or colloids to maintain normovolemia and around 25-30%, thereby diluting circulating red cells and minimizing their loss during ; the autologous is reinfused postoperatively. Systematic reviews confirm it decreases allogeneic transfusion requirements by 40-50% in cardiac and major orthopedic cases, with preserved oxygen delivery due to compensatory increases. Efficacy depends on patient baseline and anticipated loss exceeding 1 liter, but it requires careful monitoring to avoid from hemodilution. Hypotensive anesthesia induces deliberate reduction to 50-65 mmHg via vasodilators like nitroprusside or anesthetics, decreasing perfusion pressure and thus capillary oozing while preserving vital organ flow through autoregulation. Meta-analyses report average intraoperative blood loss reductions of 169 mL in orthopedic and maxillofacial procedures, with no significant increase in renal or cerebral ischemia when titrated properly. This technique complements other methods but demands invasive monitoring and is avoided in patients with coronary disease due to myocardial oxygen demand-supply mismatch risks. Pharmacological agents target and platelet function; , an , inhibits plasminogen activation, stabilizing clots and reducing surgical blood loss by 30-40% in trials across orthopedic and cardiac operations. Its widespread adoption followed the 2010 CRASH-2 trial, which enrolled 20,211 trauma patients and showed a 1.5% absolute mortality reduction (14.5% vs. 16%) from bleeding when administered within 3 hours, without excess thrombosis.60835-5/fulltext) Dosing typically involves 1 g IV bolus followed by infusion, with approval for hemostatic use dating to 1985 in select indications. Surgical innovations enhance through device-mediated sealing. The harmonic scalpel employs ultrasonic vibration at 55 kHz to denature proteins and coagulate vessels up to 5 mm, yielding blood loss reductions of 20-50 mL in meta-analyses of and cardiac resections compared to conventional methods. beam coagulators deliver monopolar radiofrequency via ionized gas for non-contact surface hemostasis, achieving rapid coagulation depths of 2-3 mm on diffuse oozing sites like liver or , superior to bipolar forceps in experimental models for speed and char reduction. Minimally invasive approaches, including and , limit dissection planes and vascular trauma, consistently halving blood loss versus open equivalents in gynecologic and colorectal trials through smaller incisions and pneumoperitoneum-reduced . These tools integrate with multimodal protocols, amplifying conservation when combined.

Postoperative Care Strategies

Postoperative monitoring in bloodless surgery emphasizes early detection of through point-of-care viscoelastic assays, such as (TEG) or rotational (ROTEM), which provide real-time evaluation of dynamics to guide precise fluid resuscitation and distinguish coagulopathic from surgical sources. Targeted fluid management protocols, informed by these assays alongside hemodynamic parameters like lactate levels and stroke volume variation, minimize dilutional while supporting endogenous recovery without volume-expanding transfusions. To address postoperative , fibrinogen concentrates and prothrombin complex concentrates (PCC) serve as targeted adjuncts, offering rapid correction equivalent to or surpassing (FFP) in hemostatic efficacy with lower infusion volumes. A 2022 multicenter randomized trial in patients demonstrated PCC reduced postoperative blood loss by approximately 200 mL and allogeneic transfusion rates by 30% compared to FFP, without increased thrombotic events. Similarly, a 2013 prospective study in trauma patients reported fibrinogen concentrate administration restored levels above 1.5 g/L, achieving hemorrhage control in 80% of cases versus 50% with plasma-based therapy, supporting its role in transfusion-free protocols. These interventions align with enhanced recovery metrics, including shortened (ICU) stays of 1-2 days in bloodless cohorts, linked to circumventing transfusion reactions such as acute lung injury or hemolytic events that prolong and organ support. In Jehovah's Witness patients undergoing cardiac procedures without transfusions, mean ICU duration averaged 2.5 days versus 4 days in transfused comparators, with reduced hours attributed to absent immunomodulatory effects. Protocols fostering hematopoiesis, via analogs and iron supplementation when nadir exceeds 7 g/dL, further expedite discharge by accelerating response, as evidenced by 20-30% faster erythropoietic recovery in non-transfused surgical series.

Clinical Applications

Cardiac and Vascular Procedures

Bloodless cardiac surgery employs techniques such as off-pump coronary artery bypass grafting (OPCAB), which avoids to minimize hemodilution, inflammation, and blood loss, often achieving intraoperative losses below 500 mL through meticulous and reduced dosing. Minimally invasive approaches to valve repair, including right mini-thoracotomy or partial sternotomy, further limit exposure and bleeding by utilizing smaller incisions and specialized retractors, resulting in reduced postoperative hemorrhage and transfusion requirements compared to conventional sternotomy. A landmark application occurred in April 2023, when completed the first bloodless heart transplant in a Jehovah's Witness patient, relying on advanced organ perfusion systems, topical hemostatics, and intraoperative cell salvage without allogeneic transfusions, with the patient achieving full recovery. In vascular procedures, endovascular techniques like thoracic endovascular aortic repair (TEVAR) and fenestrated endovascular aneurysm repair (FEVAR) predominate for blood conservation, as these percutaneous methods avoid large open fields, limiting blood loss to under 300 mL in many cases through imaging-guided deployment and selective . Meta-analyses of bloodless , primarily in Jehovah's Witness cohorts refusing transfusions, demonstrate comparable short-term outcomes to transfused patients, including 30-day mortality rates of 2-5% and similar rates of reoperation for or renal complications, attributable to rigorous preoperative optimization and intraoperative conservation. These findings hold across high-risk subgroups, though success hinges on institutional expertise in patient blood management protocols.

Orthopedic and Trauma Surgeries

In elective orthopedic procedures such as total knee arthroplasty (TKA), application establishes a bloodless surgical field, substantially reducing intraoperative blood loss by occluding arterial inflow while permitting venous drainage. Bipolar sealers further enhance through radiofrequency energy that denatures proteins in vessel walls, with randomized trials demonstrating significantly lower total blood loss and postoperative decreases compared to conventional electrocautery alone. These techniques, combined with preoperative optimization like administration, enable transfusion-free outcomes in most patients, particularly when baseline exceeds 13 g/dL. Similar strategies apply to total hip arthroplasty, where meticulous dissection, hypotensive anesthesia, and hemostatic agents minimize cumulative loss, often keeping total perioperative under 500 mL in optimized cases. Intraoperative cell salvage systems recover and reinfuse shed after washing and , further conserving autologous volume without allogeneic risks. In trauma surgeries involving orthopedic injuries, such as femoral fractures or pelvic disruptions, bloodless protocols emphasize rapid via packing, ligation, and topical agents like sealants, integrated with damage control orthopedics to stage definitive fixation after initial stabilization. data from and conflicts in the highlight the efficacy of these approaches, including early use and blood salvage devices, which reduced transfusion requirements and mortality in hemorrhagic shock by prioritizing over component therapy. Transfusion avoidance in these settings correlates with reduced deep vein thrombosis (DVT) incidence, as allogeneic infusions independently elevate venous thromboembolism risk through hemodilution, inflammatory priming, and , with meta-analyses reporting odds ratios up to 1.5 for postoperative VTE. Bloodless cohorts exhibit DVT rates below 2%, versus 5-10% in transfused orthopedic trauma patients, underscoring causal links from empirical outcome data.

Oncologic and Transplant Operations

In oncologic surgeries, particularly hepatic resections for tumors, blood conservation is challenged by hypervascular lesions and potential major vessel involvement, necessitating techniques like the Pringle maneuver—which intermittently clamps the hepatic pedicle to reduce inflow—or total vascular exclusion (TVE), which isolates the liver from systemic and splanchnic circulation while preserving cavocaval continuity. TVE enables parenchymal transection with minimal hemorrhage, as backflow from is controlled, allowing resection near the without transfusion in select cases. In optimized patients with preoperative (EPO) stimulation and intraoperative cell salvage, blood loss during these procedures has been reported as low as 30-500 mL, staying under 1 L even in major resections. For organ transplantation, bloodless approaches in liver and kidney procedures incorporate veno-venous bypass (VVB) to mitigate hemodynamic instability from inferior vena cava clamping, redirecting portal and lower body venous return during the anhepatic phase. Preoperative EPO administration, often combined with iron supplementation, raises hemoglobin levels to 10-12 g/dL, reducing reliance on intraoperative fluids or hemodilution. Orthotopic liver transplantation without blood products has been successfully performed in Jehovah's Witnesses cohorts, using conventional techniques with VVB and meticulous hemostasis, yielding no increased operative mortality. Graft outcomes in bloodless transplants mirror conventional series, with one-year and graft exceeding 90% in reported liver cases, though protocols emphasize rapid reperfusion to limit cold ischemia time below 8 hours. Ischemia-reperfusion injury (IRI) demands heightened monitoring in these settings, as preoperative and avoidance of transfusion buffers may amplify and endothelial damage upon revascularization, potentially elevating early graft dysfunction risk despite comparable long-term patency. Techniques like normothermic machine perfusion are increasingly integrated to attenuate IRI in bloodless protocols, preserving graft viability without sanguineous support.

Evidence of Efficacy

Short-Term Outcomes and Mortality Data

In risk-adjusted analyses of patients undergoing surgery within structured bloodless programs, rates have been reported as lower than in matched transfused cohorts. A multicenter study of over 1,600 patients found 30-day mortality of 0.7% in the bloodless group versus 2.7% in controls (p=0.046), with the difference primarily driven by surgical subgroups amenable to preoperative optimization. This reduction aligns with avoidance of transfusion-associated risks, though causality requires accounting for toward healthier elective candidates in such programs. A 2022 retrospective review of adult patients at , comparing 363 bloodless cases to 1,089 standard-care matches, demonstrated equivalent short-term mortality and major morbidity rates, including rates of , , and renal failure. However, bloodless patients exhibited lower incidences of hospital-acquired infections, such as and , potentially attributable to the immunomodulatory effects of allogeneic transfusions, which can suppress host defenses and increase susceptibility to nosocomial pathogens. Subgroup analyses from cohorts underscore context-dependent outcomes: elective procedures show pronounced mortality benefits (e.g., 1.7% versus 3.4% in transfused patients, p=0.005), reflecting effective blood conservation in optimized settings, whereas emergent high-bleed scenarios yield neutral results, with no significant divergence after risk adjustment. These findings hold across peer-reviewed data but highlight limitations in generalizing to unoptimized refusal cases, where unadjusted Jehovah's Witness cohorts occasionally report elevated 30-day mortality (e.g., 9.9% versus 3.5%). Overall, risk-adjusted evidence supports comparable or improved short-term survival in programmatic bloodless approaches versus standard transfusion practices.

Long-Term Survival and Complication Rates

In cohorts of undergoing without transfusions, long-term survival rates have been reported as comparable to or exceeding those of transfused controls when adjusted for patient selection biases, such as religious motivation influencing preoperative optimization and compliance. A 2020 review of outcomes cited a study by Pattakos et al. showing 5-year survival of 86% in Witnesses versus 74% in matched controls, with 10-year rates of 69% versus 59%; these differences persisted after propensity matching for transfusion avoidance propensity, suggesting bloodless techniques do not confer excess mortality risk and may mitigate transfusion-associated . Similarly, a 2012 analysis of over 1,700 patients found no increased long-term mortality hazard (adjusted HR 0.96, 95% CI 0.74-1.25) among transfusion refusers compared to transfused patients when stratified by actual transfusion status rather than religious affiliation alone, isolating bloodless protocol effects from confounding healthier baseline characteristics in Witnesses. Chronic complications appear reduced in bloodless approaches due to avoidance of transfusion-related risks, including alloimmunization and , which can precipitate delayed hemolytic reactions or organ damage years post-procedure. For instance, Jehovah's Witness series report alloimmunization rates near 0% long-term, contrasting with 10-30% incidence in transfused cohorts from repeated exposures fostering antibody formation against donor antigens. However, potential sequelae from perioperative anemia—such as subclinical tissue hypoxia leading to accelerated vascular aging or cognitive decline—remain understudied, with some observational data indicating no elevated incidence of late anemia-related events like when is aggressively managed pre- and postoperatively, though causal attribution is confounded by shorter follow-up in high-risk bloodless cases. Meta-evidence from systematic reviews reinforces neutral or favorable long-term profiles for bloodless surgery across procedures, with no consistent signal of heightened mortality when protocols emphasize stimulation, acute normovolemic hemodilution, and cell salvage to minimize nadir below 7 g/dL. A 2023 of cardiac outcomes in Witnesses versus non-Witnesses found equivalent 5-year survival (pooled OR 1.05, 95% CI 0.88-1.25) and lower rates of chronic renal complications attributable to transfusion , attributing benefits to reduced inflammatory cascades from stored products. These findings hold after excluding elective low-risk cases, but gaps persist in non-cardiac applications like , where transfusion avoidance may enhance survival via preserved immune surveillance, though randomized are absent due to ethical barriers in refusal cohorts.

Economic and Resource Impacts

Bloodless surgery programs yield substantial economic benefits by averting the high costs associated with allogeneic blood transfusions, which average $500 to $1,500 per unit of red blood cells when including hospital acquisition, processing, testing, and administration expenses. For example, implementation of patient blood management strategies, integral to bloodless approaches, has resulted in annual cost reductions of $582,039 to $873,058 at institutions like Johns Hopkins, with 93% of savings stemming directly from fewer red blood cell transfusions. These reductions compound across high-volume surgical centers, where transfusion avoidance in elective procedures can lower per-case expenditures by hundreds to thousands of dollars. Shorter lengths of hospital stay further amplify resource efficiencies, with bloodless patients typically requiring 1 to 3 fewer days of due to minimized complications and accelerated recovery. Institutional analyses report corresponding decreases in overall operational costs, including bed occupancy and ancillary services. Beyond direct care, bloodless protocols diminish reliance on inventories, curtailing waste from product expiration and storage—factors that can account for up to 10-20% of blood supply expenses in traditional models. Preoperative use of and other pharmaceuticals incurs initial costs of several hundred dollars per patient, yet these are outweighed by transfusion-related savings in the majority of applications, with net positive budget impacts observed in over 70% of implemented programs per hospital-based evaluations. Comprehensive patient blood management, encompassing bloodless techniques, has demonstrated ratios exceeding 7:1 in anesthesia-led initiatives, underscoring viability despite variable upfront demands.

Criticisms and Limitations

Clinical Risks in High-Blood-Loss Scenarios

In scenarios involving massive hemorrhage, such as emergency trauma or ruptured aortic aneurysms exceeding 50% of total blood volume loss, bloodless surgical techniques face substantial challenges due to the rapid onset of and inadequate oxygen delivery. Empirical data from trauma registries indicate that uncontrolled hemorrhage accounts for approximately 30-40% of trauma-related mortality, with up to 50% of deaths occurring pre-hospital and the majority within the first six hours post-injury, underscoring the limitations of non-transfusional strategies in restoring circulatory volume and clotting factors swiftly. Without allogeneic blood products, survival rates in patients requiring massive (e.g., equivalent to 50 or more units) drop below 50% even with transfusions, implying near-certain fatality in bloodless approaches where adjuncts like hemodilution or cell salvage cannot compensate for acute . Aortic rupture or acute type A similarly heightens risks, as these procedures inherently provoke extensive from tissue trauma and , often necessitating blood products to mitigate postoperative exceeding 2-3 liters. Studies on high-risk vascular surgeries report routine reliance on transfusions to counteract dilutional and , with bloodless attempts correlating to prolonged and multi-organ dysfunction in cases of uncontrolled loss. Patients with end-stage liver disease undergoing exhibit exacerbated under bloodless protocols, despite adjuncts like or thromboelastography-guided , owing to baseline deficiencies in procoagulant factors and compounded by intraoperative hemodilution. This population faces a rebalanced but precarious hemostatic state, where risks during invasive procedures rise due to impaired synthesis of clotting elements, leading to higher rates of intraoperative hemorrhage and postoperative failure even with optimized preoperative . Fundamentally, levels below 7 g/dL in high-blood-loss contexts precipitate critical reductions in oxygen-carrying capacity, with arterial oxygen content falling to thresholds that induce tissue hypoxia and sequential organ failure, as evidenced by increased sequential organ failure assessment scores in critically ill patients. This physiological limit—where compensation fails to avert ischemic injury to vital organs—renders bloodless methods untenable without rapid restoration of red cell mass, particularly in hemodynamically unstable patients.

Ethical Debates on Transfusion Refusal

The ethical debates surrounding transfusion refusal center on the conflict between patient —the right to make informed decisions about one's body—and medical paternalism, which emphasizes physicians' duty to preserve life through interventions like blood transfusions. Proponents of autonomy argue that competent adults should have the final say, even if refusal risks death, as forcing treatment violates and personal convictions. This view draws support from legal precedents affirming as paramount, provided alternatives are pursued to optimize outcomes without transfusion. Opponents, however, contend that refusal undermines the Hippocratic principle of non-maleficence, particularly when patients lack full capacity or when refusal stems from indoctrination rather than reasoned choice, potentially shifting the burden of death onto healthcare providers. A primary basis for refusal stems from religious convictions, notably among , who interpret biblical texts such as Leviticus 17:14 and :28-29 as prohibiting the or use of , viewing it as sacred and reserved for divine disposal rather than human sustenance. This stance equates transfusion with violating God's law, leading Witnesses to accept bloodless techniques but reject allogeneic or autologous and major components. Secular arguments reinforce by highlighting transfusion risks, including transfusion-related acute lung injury (TRALI), with an incidence of approximately 1 in 5,000 transfusions, alongside other complications like infections and that can exacerbate morbidity. These risks, empirically documented, suggest that refusal is not irrational but a weighing of harms, especially given that conservative management and alternatives yield comparable survival in many scenarios. Legally, courts have largely upheld adult refusals while mandating exhaustive non-transfusion efforts, as seen in a 2024 ruling affirming a Jehovah's Witness's right to decline transfusion despite life-threatening , deeming forced administration a violation of and religious . Similar U.S. cases, such as In re Estate of Brooks (1965), permitted judicial override only for incompetents, establishing that competent adults' directives prevail absent coercion. For minors, however, often dominates; courts frequently authorize transfusions against parental wishes, prioritizing the child's best interest, as in a 2019 decision overriding a 14-year-old Jehovah's Witness's due to maturity concerns and imminent risk. These rulings balance with protection, requiring proof of informed refusal and institutional readiness for alternatives. Critics of unbridled invoke a duty-to-treat ethic, arguing that physicians cannot abet potentially preventable deaths, especially amid perceptions of transfusion overuse driven by habitual practice rather than necessity—evidenced by a nearly one-third decline in U.S. transfusions from 2000 to 2013 due to restrictive guidelines reducing unnecessary units. Yet, empirical outcomes from bloodless protocols indicate viability for most elective and even high-risk cases, supporting without routine paternalistic override, provided patients acknowledge optimized care. This realism acknowledges that while transfusions save lives in acute hemorrhage, over-reliance—sometimes incentivized by economics—has normalized interventions with non-zero risks, tilting the debate toward respecting refusals in competent adults.

Evidence Gaps and Methodological Concerns

pervades much of the observational research on bloodless surgery, as patients electing these protocols, particularly , often represent a self-selected cohort with potentially better baseline health or lower surgical risk, leading to overly optimistic outcome reports. studies frequently fail to include unmatched controls or exclude higher-risk individuals who decline or are denied procedures, confounding comparisons with transfused populations. For instance, patients may receive care from more experienced surgical teams, further skewing results in favor of bloodless approaches without isolating technique-specific effects. Randomized controlled trials remain exceedingly rare in bloodless surgery , primarily due to ethical constraints against withholding transfusions in high-bleed scenarios, resulting in heavy dependence on non-randomized, retrospective prone to unmeasured such as preoperative optimization biases or variable institutional protocols. has been employed in some analyses to approximate balance, yet these methods cannot fully eliminate residual confounding from unrecorded variables like or comorbid frailty. Calls persist for more rigorous, risk-adjusted designs to disentangle bloodless techniques from patient selection artifacts. Notable evidence gaps exist in pediatric populations and ultra-high-risk adult cases, where data are sparse and largely limited to small case series rather than large-scale, comparative studies. Pediatric bloodless care, for example, shows comparable short-term outcomes in select reports but lacks longitudinal follow-up and controls for developmental vulnerabilities like lower physiological reserves. High-risk subgroups, including those with severe preoperative or complex multivisceral procedures, remain understudied, with experts advocating propensity-matched cohorts to address these voids and better quantify applicability limits.

Institutional Implementation

Hospital Bloodless Programs

Hospital bloodless programs typically involve coordinated multidisciplinary teams comprising hematologists, surgeons, anesthesiologists, perfusionists, and nursing staff to implement patient blood management strategies that minimize or eliminate the need for allogeneic transfusions. These teams develop preoperative optimization protocols, such as correction and volume expansion, alongside intraoperative techniques like cell salvage and minimally invasive surgery, and postoperative monitoring. At , the Center for Bloodless Medicine and Surgery integrates specialists across departments to provide comprehensive care for patients refusing transfusions, emphasizing education and case-specific planning. NYU Langone Health's Bloodless Medicine and Surgery Program employs advanced technologies and blood conservation methods, with physicians trained in transfusion alternatives for procedures ranging from cardiac to orthopedic surgeries. operates bloodless programs at facilities like Washington Hospital Center, established in 2011, and offers international consulting to replicate such models, focusing on non-blood alternatives for high-risk cases. Protocols in these programs are often standardized through guidelines from the Society for the Advancement of Patient Blood Management (SABM), founded in 2001, which promotes evidence-based practices for optimizing patient outcomes via blood conservation. SABM's administrative and clinical standards outline multidisciplinary workflows, including preoperative assessment and transfusion thresholds, adopted by member institutions to ensure consistency and safety. In a recent implementation, Good Samaritan 's Bloodless Surgery Program achieved a 41% reduction in blood transfusions compared to prior years, projecting only 2,000 units of red blood cells transfused system-wide in 2025 through enhanced conservation techniques.

Patient Advocacy and Accessibility

have played a pivotal role in advancing bloodless surgery through their Hospital Liaison Committees, which offer legal assistance, educational resources on transfusion alternatives, and coordination with medical staff to uphold patient refusals of blood products. These committees facilitate pre-surgical planning and advocate for accommodations in policies, contributing to the institutionalization of blood conservation protocols without compromising doctrinal adherence. This advocacy has spurred policy shifts emphasizing , enabling broader application beyond religious contexts to patients citing personal, medical, or ethical objections to transfusions. Non-religious individuals increasingly access bloodless options via patient blood management programs that prioritize minimizing allogeneic blood use, supported by legal frameworks affirming in treatment decisions. By the 2020s, roughly 5% of U.S. hospitals maintained dedicated bloodless surgery programs, reflecting gradual expansion driven by such advocacy, though coverage remains uneven. Accessibility challenges include geographic disparities, with rural regions facing fewer programs due to limited specialized facilities and workforce shortages. Surgeon training deficiencies compound this, as proficiency in bloodless techniques demands targeted education often absent from standard residency programs, restricting equitable rollout.

References

  1. https://pubmed.ncbi.nlm.nih.gov/11460783/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6596379/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4234090/
  4. https://pubmed.ncbi.nlm.nih.gov/37716536/
  5. https://www.sciencemuseum.org.uk/objects-and-stories/medicine/problem-blood-loss
  6. https://www.baus.org.uk/museum/1325/19th_century
  7. https://history.physio/the-bloodless-surgeon-of-vienna/
  8. https://stanfordbloodcenter.org/a-brief-history-of-blood-transfusion-through-the-years/
  9. https://pubmed.ncbi.nlm.nih.gov/9265899/
  10. https://aob.amegroups.org/article/view/6747/html
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5498987/
  12. https://www.namisurgical.com/2025/06/13/the-evolution-of-surgical-tools-understanding-our-past-to-inform-the-future/
  13. https://www.anesthesiologynews.com/Commentary/Article/12-22/U-S-Army-Anesthesia-in-World-War-II/68801?ses=ogst
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC9298489/
  15. https://journals.sagepub.com/doi/full/10.1177/0310057X19860161
  16. https://www.bjaed.org/article/S2058-5349%252820%252930157-8/fulltext
  17. https://asatt.memberclicks.net/assets/docs/2021sensors/2021FallSensor_IntraoperativeCellSalvage_withQuiz.pdf
  18. https://www.englewoodhealth.org/service/bloodless-medicine-and-surgery
  19. https://www.nytimes.com/1998/04/21/science/bloodless-surgery-gains-new-acceptance.html
  20. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa
  21. https://www.ncbi.nlm.nih.gov/books/NBK554547/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2727532/
  23. https://openanesthesiajournal.com/contents/volumes/V9/TOATJ-9-6/TOATJ-9-6.pdf
  24. https://www.anesthesiologynews.com/Clinical-Anesthesiology/Article/02-21/Bloodless-Medicine-Program-Demonstrates-Lower-Infections-Than-Standard-of-Care/62444
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10960207/
  26. https://www.uptodate.com/contents/perioperative-blood-management-strategies-to-minimize-transfusions
  27. https://journals.sagepub.com/doi/full/10.1177/2151459320935094
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6044356/
  29. https://www.sciencedirect.com/science/article/pii/S2531137921000067
  30. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001285
  31. https://wjes.biomedcentral.com/articles/10.1186/s13017-024-00554-7
  32. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.14466
  33. https://pubmed.ncbi.nlm.nih.gov/31903592/
  34. https://thejns.org/spine/view/journals/j-neurosurg-spine/33/2/article-p261.xml
  35. https://www.bjanaesthesia.org.uk/article/S0007-0912%2817%2933465-7/fulltext
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3592192/
  37. https://www.nejm.org/doi/full/10.1056/NEJMoa2504948
  38. https://pubmed.ncbi.nlm.nih.gov/27542543/
  39. https://www.sciencedirect.com/science/article/pii/S2405857220301194
  40. https://pubmed.ncbi.nlm.nih.gov/26448897/
  41. https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-023-02057-9
  42. https://pubmed.ncbi.nlm.nih.gov/1920562/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4492142/
  44. https://bjssjournals.onlinelibrary.wiley.com/doi/10.1002/bjs.11393
  45. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/am-pdf/10.1111/anae.13765
  46. https://www.asahq.org/~/media/sites/asahq/files/public/resources/standards-guidelines/practice-guidelines-for-perioperative-blood-management.pdf
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC9244769/
  48. https://sjtrem.biomedcentral.com/articles/10.1186/1757-7241-21-74
  49. https://www.revespcardiol.org/en-bloodless-cardiac-surgery-in-jehovahs-wi-articulo-13109916
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC11251377/
  51. https://www.jchestsurg.org/journal/view.html?uid=212&vmd=Full
  52. https://pubmed.ncbi.nlm.nih.gov/22486150/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3625540/
  54. https://my.clevelandclinic.org/health/treatments/17234-minimally-invasive-mitral-valve-repair
  55. https://advances.massgeneral.org/cardiovascular/article.aspx?id=1537
  56. https://pubmed.ncbi.nlm.nih.gov/18544304/
  57. https://pubmed.ncbi.nlm.nih.gov/37172869/
  58. https://www.sciencedirect.com/science/article/pii/S0146280623002062
  59. https://www.sciencedirect.com/science/article/pii/S2059775421002091
  60. https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/038120179e.pdf
  61. https://www.arthroplastytoday.org/article/S2352-3441%2824%2900194-8/fulltext
  62. https://www.arthroplastyjournal.org/article/S0883-5403%2824%2900994-X/abstract
  63. https://pubmed.ncbi.nlm.nih.gov/29470190/
  64. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.12056
  65. https://www.thrombosisresearch.com/article/S0049-3848%2824%2900113-0/fulltext
  66. https://josr-online.biomedcentral.com/articles/10.1186/s13018-021-02510-6
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4065915/
  68. https://karger.com/dsu/article/24/4/274/115449/Vascular-Occlusion-Techniques-during-Liver
  69. https://link.springer.com/article/10.1007/BF02672260
  70. https://www.sciencedirect.com/science/article/pii/S1365182X1530705X
  71. https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-020-0945-x
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC3022432/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC9455584/
  74. https://www.nature.com/articles/s41419-021-03878-3
  75. https://www.sciencedirect.com/science/article/pii/S1600613522094710
  76. https://pubmed.ncbi.nlm.nih.gov/24942198/
  77. https://pubmed.ncbi.nlm.nih.gov/35977366/
  78. https://www.hopkinsmedicine.org/-/media/bloodless-medicine-surgery/documents/bloodless-papers/frankresar2022bloodlessoutcomes.pdf
  79. https://pubmed.ncbi.nlm.nih.gov/17803571/
  80. https://pubmed.ncbi.nlm.nih.gov/29616523/
  81. https://journals.sagepub.com/doi/full/10.1177/0267659120980375
  82. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1211993
  83. https://pubmed.ncbi.nlm.nih.gov/36401716/
  84. https://www.annalsthoracicsurgery.org/article/S0003-4975%2811%2901538-4/fulltext
  85. https://www.sciencedirect.com/science/article/abs/pii/S0146280623004954
  86. https://needsblood.com/view_blog.php?id=34
  87. https://www.stjude.org/care-treatment/treatment/clinics-services/blood-donor-center/why-should-i-donate-blood.html
  88. https://www.aabb.org/docs/default-source/default-document-library/resources/pbm-the-benefits-of-pbm-for-the-patient-and-the-health-care-system.pdf?sfvrsn=3ccf0957_4
  89. https://www.medstarhealth.org/blog/bloodless-transfusions
  90. https://pesquisa.bvsalud.org/portal/resource/pt/sea-214812
  91. https://www.ormanagement.net/Clinical-News/Article/12-23/Blood-Management-Program-Yields-Significant-Cost-Savings-Comparable-Patient-Outcomes/72402
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC10838852/
  93. https://pubmed.ncbi.nlm.nih.gov/38110651/
  94. https://www.asahq.org/about-asa/newsroom/news-releases/2023/10/anesthesiologist-led-blood-management-programs
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC3929186/
  96. https://www.nature.com/articles/s41598-025-89139-1
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC6078469/
  98. https://www.uth.edu/news/story/limitless-whole-blood-best-for-trauma-patients-with-severe-blood-loss-according-to-new-uthealth-houston-research
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC5827279/
  100. https://www.annalsthoracicsurgery.org/article/S0003-4975%2804%2900700-3/fulltext
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC5040944/
  102. https://ashpublications.org/blood/article/116/6/878/27617/Rebalanced-hemostasis-in-patients-with-liver
  103. https://journals.lww.com/anesthesia-analgesia/fulltext/2018/01000/the_coagulation_profile_of_end_stage_liver_disease.15.aspx
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC7045194/
  105. https://www.atsjournals.org/doi/10.1513/AnnalsATS.202109-1078OC
  106. https://www.sciencedirect.com/science/article/pii/S0887796325000197
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC3934270/
  108. https://www.jw.org/en/jehovahs-witnesses/faq/jehovahs-witnesses-why-no-blood-transfusions/
  109. https://smj.org.sa/content/46/8/865
  110. https://www.courthousenews.com/jehovahs-witness-deserved-the-right-to-refuse-blood-transfusion-europes-rights-court-rules/
  111. https://firstamendment.mtsu.edu/article/blood-transfusions-and-medical-care-against-religious-beliefs/
  112. https://hcup-us.ahrq.gov/reports/statbriefs/sb215-Red-Blood-Cell-Transfusions-Trends.jsp
  113. https://www.ccjm.org/content/ccjom/64/9/475.full.pdf
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC8446884/
  115. https://www.jcvaonline.com/article/S1053-0770%2823%2900272-0/fulltext
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC10420128/
  117. https://anesthesiaexperts.com/bloodless-medicine-surgery-top-10/
  118. https://pubmed.ncbi.nlm.nih.gov/38175737/
  119. https://www.hopkinsmedicine.org/-/media/bloodless-medicine-surgery/documents/bloodless-papers/lopedsbloodless.pdf
  120. https://www.medstarhealth.org/news-and-publications/articles-and-research-reports/bloodless-medicine-and-surgery
  121. https://www.uchicagomedicine.org/conditions-services/heart-vascular/heart-surgery/bloodless-heart-surgery
  122. https://www.hopkinsmedicine.org/center-for-bloodless-medicine-and-surgery
  123. https://nyulangone.org/care-services/bloodless-medicine-surgery-program
  124. https://www.medstarhealth.org/locations/bloodless-medicine-and-surgery-medstar-washington-hospital-center
  125. https://www.medstarhealth.org/innovation-and-research/international-training-center-for-bloodless-medicine
  126. https://www.sabm.org/who-we-are-
  127. https://www.sabm.org/assets/pdfs/SABM-Standards-20196.pdf
  128. https://www.wmchealth.org/press-releases/good-samaritan-hospitals-bloodless-surgery-program-achieves-41-reduction-in-blood-transfusions
  129. https://www.jw.org/en/medical-library/medical-information/hospital-liaison-committees/hln/
  130. https://www.facs.org/about-acs/statements/recommendations-for-surgeons-caring-for-patients-who-are-jehovah-s-witnesses/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC3369324/
  132. https://www.rcseng.ac.uk/-/media/files/rcs/library-and-publications/non-journal-publications/caring-for-patients-who-refuse-blood--a-guide-to-good-practice.pdf
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC11679254/
  134. https://www.facs.org/for-medical-professionals/practice-management/private-practice-small-business/rural-surgery-practice/
Add your contribution
Related Hubs
User Avatar
No comments yet.